Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

50 adult patients with moderate to severe plaque psoriasis will be given OTEZLA® for 16 weeks with add-on Enstilar.

Inclusion criteria

• Male or female adult ≥ 18 years of age;
• Diagnosis of chronic plaque-type psoriasis
• Moderate to severe plaque type psoriasis as defined at baseline by:

• PGA score of 3 or greater
• BSA affected by plaque-type psoriasis of 10% or greater
• PASI ≥ 12
• Able and willing to give written informed consent prior to performance of any study-related procedures
• Must be in general good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, clinical laboratories, and urinalysis. (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions).

Exclusion criteria

• Other than psoriasis, any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is uncontrolled.
• Forms of psoriasis other than chronic plaque-type (e.g., Pustular erythrodermic and/or guttate psoriasis) or drug induced psoriasis
• Subjects who previously used any biologic agent for psoriasis.
• Use of oral systemic medications for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin and cyclosporine).
• Patient used topical therapies to treat psoriasis on the hands and/or feet within 2 weeks of the Baseline Visit (includes, but not limited to, topical corticosteroids, vitamin D analogs, or retinoids).
• Patient received UVB phototherapy within 2 weeks of Baseline.